Skip to main content

Table 5 Mucosal melanoma of the head and neck: a review of the recent literature series (with ≥50 patients & utilizing radiotherapy)

From: Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013

Author Setting, country Period of diagnosis No. of patients Age Primary tumor site (%) TNM stage (%) Treatment modality (%) OS (at 5 years, %) DSS, (at 5 years, %)
Median/Mean* (range)
Gal et al., 2011 [29] Population-based (26 %), USA 2000–2007 304 71.2* SN, all III, 32.2 S, 43.1 24.2 NR
IVA, 25.3 SRT, 38.5
IVB, 11.2 RT, 7.6
IVC, 12.2 None/Unknown, 10.9
Jangard et al., 2013 [13] Population-based (96 %), Sweden 1960–2000 186 72 (31–93) SN, all I, 83.9 S, 53.1 NR 20.4
II, 2.2 SRT, 32
III, 4.3, SRTSTh, 2.7
Unknown, 9.7 Palliative, 12.2
Benlyazid et al., 2010 [30] Multi-institutional, France 1980–2008 160 67.0 (30–93) SN, 90.6 I, 96.3 S, 51.3 37.5 NR
OC, 7.5 II, 3.8 SRT, 48.8
Other, 1.9
Lund et al., 2012 [27] Single institution, UK 1963–2010 115 65.9* (15–91) SN, all I, 87.8 S, 55.7 28 NR
II, 8.7 Unknown, 3.5 SRT, 44.3
Shiga et al., 2012 [31] Multi-institutional, Japan 1998–2007 94 68.4* (37–96) SN, 78.7 I, 16.0 S, 9.6 S + STh/RT, 38.6 NR
      OC-OP, 15.6 II, 28.7 RT, 9.6 RT+/−STh, 29.9
      Unknown primary, 3.2 External ear, 2.1 III, 9.6 STh, 7.4
       IVA, 31.9 S + STh/RT, 52.1
       IVB, 3.2 RT+/−STh, 19.1
       IVC, 10.6 None, 2.1
Meng et al., 2014 [32] Single institution, China 2000–2010 69 65.9* (28–89) SN, all III, 53.6 S, 39.1 S, 31.6 NR
IVA, 39.1 SRT, 34.8 SRT, 55
IVB, 7.2 SRTSTh, 26.1 SRTSTh, 32.1
Sun et al., 2014 [33] Single institution, China 1976–2005 68 55 (2–79) SN, all III, 52.9 S, 27.7 29.7 NR
IVA, 35.3 RT, 6.2
IVB, 5.9 STh, 12.3
IVC, 5.9 SRT, 20.0
S + STh, 29.2
RT + STh, 3.1
SRTSTh, 1.5
Douglas et al., 2010 [34] Single institution, UK 1965–2001 68 63 (29–86) SN, 65 I, 80 S, 27 22 32
OC, 19 II, 19 RT, 46
Other, 16 III, 1 SRT, 7
Palliative, 20
Demizu et al., 2014 [35] Single institution, Japan 2003–2011 62 70.5 (33–89) SN, 90.3 T1, 27 RT, all At 1 year, 93 NR
OC, 9.7 T2, 31 - protons, 53.2 At 2 years, 61
T3, 31 - carbon ion, 46.8
T4, 11 Prior treatment:
S, 11.3
STh, 8.1
S + STh, 3.2
Moreno et al., 2010 [19] Single institution, USA 1993–2004 58 63.4 (38–93) SN, all I, 87.9 S, 43.1 38.7 18.4
II, 6.9 SRT, 53.4
III, 5.2 RT, 3.4
Shuman et al., 2011 [28] Single institution, USA 1992–2009 52 66* OC, 31 I, 25.0 S, 69.2 38 22
SN, 69 II, 34.6 SRT, 19.2
III, 11.5 Palliative RT, 9.6
IV, 28.8
Sun et al., 2012 [36] Single institution, China 1976–2005 51 55 (31–75) OC, all III, 23.5 S, 76.5 20.7 NR
IVA, 34 SRT, 3.9
IVB, 4 STh, 11.8
IVC, 1 None, 7.8
Koivunen et al., 2012 [37] Multi-institutional, Finland 1990–2004 50 70* (46–93) SN, all III, 36 S, 66.0 27 48
IVA, 42 SRT, 14.0
IVB, 20 RT, 14.0
IVC, 2
Current series, 2016 Population-based, Slovenia 1986–2013 61 75.5 (25–91) SN, 72 III, 34 Curative intent Whole cohort, 18
Curative intent, 24
Curative intent, 25
OC-OP, 26 IVA, 49 (N = 48):
Middle ear, 1.6 IVB, 12 S, 44
IVC, 4.9 SRT, 33
RT, 23
  1. OS Overall survival, SN Sinonasal tract, S Surgery, SRT Surgery and postoperative radiotherapy, RT Radiotherapy, NR Not reported, SRTSTh Surgery with postoperative radiotherapy and systemic therapy, OC Oral cavity, OC-OP Oral cavity and oropharynx, STh Systemic therapy
  2. *Mean age